Ovarian Cancer Commitment
Ovarian Cancer Commitment (OCC)
The Ovarian Cancer Commitment (OCC) is an initiative launched by the European Society of Gynaecological Oncology (ESGO), the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) and AstraZeneca.
We are committed to creating a movement in ovarian cancer care through highlighting the importance of improving access to rapid diagnosis, biomarker testing and specialised care, to ultimately facilitate the improvement of the quality of life of women* living with ovarian cancer.
The OCC will provide a platform to current and future partners to pledge their commitment and implement tangible actions to help improve the experience and survival of those living with ovarian cancer.
For more information, please visit: www.ovariancancercommitment.com
*This refers to people assigned female at birth
OCC Initial Projects
- Olivia Digital Patient Support
An exclusive resource for anyone affected by ovarian cancer. Read More
- Don’t Overlook Awareness Campaign
To urge women and primary care physicians to recognise ovarian cancer symptoms and understand the importance of a rapid diagnosis as well as access to and benefits of specialist care. Read More
OCC Founding Partners Talk about the Initiative
"The OCC seeks to address the many challenges women with ovarian cancer face, to increase knowledge and access to best care, in order to ultimately improve survival and support better quality of life for ovarian cancer patients.."
Prof. Nicole Concin, ESGO President
"The OCC recognises the power of community and will act as a collective voice for everyone diagnosed with ovarian cancer, providing a vital opportunity for their views to be heard and connect people, information and resources. I do believe that together we can drive forward better outcomes.”
Petra Adamkova, Co-Chair, ENGAGe
“We are proud to join forces with the wider community to drive progress in the understanding, management and outcomes of ovarian cancer. Although significant progress has been made in recent decades, ovarian cancer is a complex problem that can only be solved through collaboration.”
Dave Fredrickson, EVP Oncology Business Unit, AstraZeneca
